Cue Biopharma reports Q3 2026 results, CUE-221 CSU data and CUE-401 dosing start
The company disclosed Phase 2 chronic spontaneous urticaria data for CUE-221 and the start of first-in-human dosing for CUE-401, alongside quarterly financials.
Cue Biopharma reported third quarter 2026 financial results and business updates on November 16, 2026. The company initiated its first-in-human Phase 1 trial of CUE-401, with dosing underway in the first cohort.1 CUE-401 is Cue's lead autoimmune candidate, designed to regulate inflammation and drive Treg-mediated tolerance.1
For CUE-221, the company's anti-IgE antibody, Cue reported topline data from a Phase 2 study in chronic spontaneous urticaria (CSU). In a prespecified subgroup of patients with high baseline IgE of 300 IU/mL or greater, 78% of patients receiving 4 mg/kg achieved complete hive resolution (HSS7=0) at week 12, versus 0% on placebo (P < 0.005).1 A post-hoc analysis also found a 67% complete response rate (UAS7=0) versus 0% for placebo (p < 0.05).1 The company said durable clinical benefit (HSS7=0) at week 28, 12 weeks after the last dose, in the 4 mg/kg group persisted without clinically meaningful drug exposure, was not seen at lower doses, and exceeded results for XOLAIR (omalizumab) in a post-hoc comparison.1
Across the Phase 1 and Phase 2 CSU studies, CUE-221 showed favorable and well-tolerated safety up to 10 mg/kg, with no neutralizing antibodies observed.1 The FDA has cleared the CUE-221 investigational new drug application for food allergy, allowing the program to advance.1
On financials, Cue had $57.9 million in cash and cash equivalents as of September 30, 2026.1 Under a Second Amendment to its license agreement with ImmunoScape, the company's right to receive a $5.0 million payment was increased to $5.5 million total, payable in installments through the fourth quarter of 2027.1 Net loss for the quarter was $50.0 million, compared to $7.4 million in the third quarter of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.